This study in 64 patients evaluated anti-emetic ondansetron versus commonly used dronabinol versus the combination of both nausea and vomiting caused by late chemotherapy (Meiri et al. 2007). The two agents seemed similar in effectiveness, without additional benefit from the combination. Therefore, in this most recent study, the cannabinoid once again performed well as the current standard anti-emetic. Many people with anxiety and depression have become interested in the natural approach to cannabis oil because they have been shown to treat these conditions without the side effects experienced with the use of other conventional medicines.

While CBD is being studied as a treatment for a wide variety of conditions, including Parkinson’s disease, schizophrenia, diabetes, multiple sclerosis and anxiety, research into the benefits of the drug is still limited. A 2006 study found that Sativex, a CBD-based botanical drug approved in the UK in 2010, promoted statistically significant improvements in sleep quality, pain during exercise and pain in patients with rheumatoid arthritis compared to placebo. It was the first controlled study of Sativex as a treatment for rheumatoid arthritis, with 58 patients. CBD was found to have an analgesic effect, as well as the ability to suppress disease activity. This disorder is characterized as a group of eye conditions that can cause damage to the optic nerve and cause loss of vision. This damage is often caused by an abnormally high intraocular pressure (NEI, n.d.).

In a recent study, patients undergoing chemotherapy used CBD oil and found that it helped reduce the side effects of chemotherapy, especially the feeling of nausea. Most of these patients also reported that CBD helped reduce their discomfort and pain. USA They indicate that CBD is effective in treating chronic and non-cancerous pain. In a 2020 study, researchers administered CBD topically to a group of patients with symptomatic peripheral neuropathy, while another group with the same condition received placebo.

Randomized studies of the efficacy of cannabidiol for various forms of epilepsy have been completed and are awaiting publication. We have identified two good quality systematic reviews (Koppel et al. 2014; Whiting et al., 2015) who evaluated medical cannabis for Tourette syndrome. Both cbd cream for pain good quality assessments identified the same tests and we focused on the most recent review by Whiting et al. . The two RCTs, conducted by the same research group (Müller-Vahl et al., 2001, 2002, 2003a, b), compared THC capsules with placebo in 36 patients with Tourette syndrome.

It was most complete, both in terms of target medical conditions and cannabinoids tested. Sneecor et al. closely focused on pain related to spinal cord injury, did not include studies with cannabis and identified only one study of cannabinoids . Two assessments of rheumatoid arthritis pain did not contribute to separate studies or findings (Fitzcharles et al. 2016; Richards et al. 2012). Finally a review (Andreae et al.2015) performed a Bayesian analysis of five primary studies of peripheral neuropathy that tested the efficacy of inhaled flower-shaped cannabis. Two of the primary studies in that assessment were also included in the Whiting review, while the other three were not. It is worth noting that the findings of all assessments were largely consistent, suggesting that cannabinoids have a modest effect on pain.

The authors of the good quality systematic review of Cochrane concluded that “the review finds no evidence that cannabinoids are effective in improving altered behavior in dementia or treating other dementia symptoms” (Krishnan et al. 2009, p. 8). We agree that evidence is limited due to the small number of enrolled patients, study design and reporting limits and inconsistent effects. The current limited evidence does not support the therapeutic effect of cannabinoids. The committee has not established a systematic assessment of good or fair quality reporting on medicinal cannabis as an effective treatment for symptoms of irritable bowel syndrome. Early evidence that analyzes the use of CBD in the treatment of anxiety and depression has produced some interesting results, although in very small samples.

Consequently, Gloss and Vickrey stated that no reliable conclusions could be drawn about the efficacy of cannabinoids for epilepsy. The renewed interest in the therapeutic effects of cannabis stems from the movement that started 20 years ago to make cannabis available as a medicine for patients with various conditions. It was in 1996 that Arizona and California first passed medical cannabis laws, although Arizona later withdrew approval, paving California the way.

In the absence of published articles reporting the results of studies conducted in patients with spasticity due to spinal cord injury, there is insufficient evidence to conclude that cannabinoids are effective in treating spasticity in this population. Oral preparations of THC from nabilon and dronabinol have been available for more than 30 years to treat chemotherapy-induced nausea and vomiting (Grotenhermen and Müller-Vahl, 2012). Both were found to be superior to placebo and equivalent to the anti-emetics available at the time the original studies were conducted. More recent research suggests that dronabinol is equivalent to ondansetron for delayed nausea and vomiting, although no comparison has been made with today’s most commonly used neuroquinin-1 inhibitors. In previous studies, patients reported a preference for cannabinoids over available agents.